WO2005097960A1 - Cetylpyridinium chloride as an antimicrobial agent in ophthalmic compositions - Google Patents

Cetylpyridinium chloride as an antimicrobial agent in ophthalmic compositions Download PDF

Info

Publication number
WO2005097960A1
WO2005097960A1 PCT/US2005/011009 US2005011009W WO2005097960A1 WO 2005097960 A1 WO2005097960 A1 WO 2005097960A1 US 2005011009 W US2005011009 W US 2005011009W WO 2005097960 A1 WO2005097960 A1 WO 2005097960A1
Authority
WO
WIPO (PCT)
Prior art keywords
solution
component
ppm
contact lens
amount effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/011009
Other languages
English (en)
French (fr)
Inventor
Zhi-Jian Yu
Stanley W. Huth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Surgical Vision Inc
Original Assignee
Advanced Medical Optics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medical Optics Inc filed Critical Advanced Medical Optics Inc
Priority to JP2007507379A priority Critical patent/JP2007532953A/ja
Priority to BRPI0509654-5A priority patent/BRPI0509654A/pt
Priority to CA2562546A priority patent/CA2562546C/en
Priority to EP05763160A priority patent/EP1733014B1/en
Priority to DE602005013498T priority patent/DE602005013498D1/de
Priority to CN200580011933XA priority patent/CN1942571B/zh
Priority to AU2005230851A priority patent/AU2005230851B2/en
Publication of WO2005097960A1 publication Critical patent/WO2005097960A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/0005Other compounding ingredients characterised by their effect
    • C11D3/0078Compositions for cleaning contact lenses, spectacles or lenses
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/14Organic compounds not covered by groups A61L12/10 or A61L12/12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/14Organic compounds not covered by groups A61L12/10 or A61L12/12
    • A61L12/143Quaternary ammonium compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/14Organic compounds not covered by groups A61L12/10 or A61L12/12
    • A61L12/143Quaternary ammonium compounds
    • A61L12/145Polymeric quaternary ammonium compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D1/00Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
    • C11D1/008Polymeric surface-active agents
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/20Organic compounds containing oxygen
    • C11D3/22Carbohydrates or derivatives thereof
    • C11D3/222Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/26Organic compounds containing nitrogen
    • C11D3/28Heterocyclic compounds containing nitrogen in the ring
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/34Organic compounds containing sulfur
    • C11D3/349Organic compounds containing sulfur additionally containing nitrogen atoms, e.g. nitro, nitroso, amino, imino, nitrilo, nitrile groups containing compounds or their derivatives or thio urea
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/48Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/34Organic compounds containing sulfur
    • C11D3/3409Alkyl -, alkenyl -, cycloalkyl - or terpene sulfates or sulfonates

Definitions

  • the present invention relates to compositions and methods for eye and contact lens care. More particularly, the invention relates to ophthalmic compositions which contain cetylpyridinium chloride as a decontaminating agent for preservation of the solution and/or disinfecting contact lenses.
  • Description of the Prior Art Contact lens wear induces adverse changes in ocular tissues and the tear film. These changes include cornea lactic acidosis and subsequent cornea swelling as a consequence of hypoxia induced by low oxygen gas transmission, changes in corneal epithelial tissue thickness, changes in corneal epithelial and endothelial cell morphology, epithelial surface cell exfoliation, hyperemia (red eye), adverse changes in corneal and conjunctival cell membrane integrity and destabihzation of the tear film.
  • CPC cetylpyridinium chloride
  • cetylpyridinium chloride (CPC) at low concentrations, in combination with a non-ionic surfactant, can be efficacious as a contact lens disinfection agent.
  • the non-ionic surfactant is a poly(oxypropylene)-poly(oxyethylene) block copolymer. Such efficacy may be seen in concentrations ranging from as low as 0.1 ppm or 0.3 ppm to about 8 ppm, 9 ppm or 10 ppm.
  • Figure 1 shows the amount of CPC uptake by Purevision® lenses (Bausch & Lomb Incorporated, Rochester New York) as a function of CPC concentration at adsorption equilibrium.
  • compositions include, in an aqueous liquid medium, a non-ionic surfactant and cetylpyridinium chloride.
  • the non-ionic surfactant is a poly(oxypropylene)-poly(oxyethylene) block copolymer.
  • Such solutions may also include one or more of the following: additional antimicrobial components, preferably reduced in concentration from the concentration that is typically used with only one antimicrobial component; a buffer component in an amount effective to maintain the pH of the solution within a physiologically acceptable range; an effective amount of a viscosity inducing component; a surfactant in an amount effective to clean a contact lens contacted with the solution; and a tonicity component in an amount effective to provide the desired tonicity to the solution.
  • the solutions may also include taurine. The benefits of including taurine are disclosed in U.S. Patent Application Ser. No. 10/328,641, to S. Huth, entitled “Contact Lens Care Compositions, Methods of Use, and Preparation which Protect Ocular Tissue," which is incorporated herein by reference.
  • the solutions of the present invention provide the desired antimicrobial activity and performance effectiveness and, importantly, substantial, preferably enhanced, lens wearer/user comfort and acceptability benefits.
  • contact lens cleaning and disinfecting solutions typically contain significant amounts of surfactants in order to clean the contact lens surface which is contaminated mainly by tear protein and lipids.
  • surfactants include non-ionic surfactants and non-ionic surfactants.
  • non-ionic surfactants are commonly used for contact lens cleaning.
  • non-ionic surfactants are also commonly used to neutralize quaternary-based antimicrobial- agents in microbiology test labs. Thus, the concentration must be carefully controlled.
  • Anionic surfactants such as soap are generally not compatible with quaternary amine based antimicrobials that are positively charged.
  • anionic surfactants would defy the microbial activity of non-polymeric based polyquaternary ammonium compounds. Electrostatic interaction between ion of the surfactant and cation of the quaternary ammonium would neutralize the net charge, eliminate the antimicrobial activity and form a precipitate due to the loss of hydrophilicity by charge neutralization.
  • j Cationic surfactants are compatible with alkyl amines, but they themselves are antimicrobial agents, and therefore cannot be added in large amounts without irritating the eye.
  • CPC is highly active in specific concentration ranges and can be used in contact lens disinfecting. That is, CPC can be used for contact lens disinfection without significantly building up in a contact lens, provided that it is used with a certain type of surfactant which functions as a cleaning and/or solubilizing agent, and the two are used according to a special mixing ratio.
  • a certain type of non-ionic surfactant, used in a certain mixing ratio can reduce CPC lens uptake while maintaining anti-microbial effectiveness for disinfection.
  • the present compositions which may be multi-purpose solutions, have a multitude of applications, for example, as disinfecting, cleaning, soaking, wetting, rewetting, rinsing, storing, in-the-eye cleaning, and conditioning compositions, for contact lens care, while providing substantial lens wearer/user comfort and acceptability.
  • the present compositions also increase user compliance, that is promote regular and consistent contact lens care, and, ultimately, lead to or facilitate better ocular health.
  • Any contact lenses for example, conventional hard contact lenses, rigid gas permeable contact lenses and soft, hydrophilic or hydrogel, contact lenses, including silicone hydrogel contact lenses, can be treated in accordance with the present invention.
  • CPC in the presence of a selected non-ionic surfactant, can be efficacious as a contact lens disinfection agent at low concentration ( ⁇ 10 ppm).
  • non-ionic surfactants for use in the present invention are disclosed in, for example, Kirk-Othmer, Encyclopedia of Chemical Technology, 3rd Edition, Vol. 22 (John Wiley E Sons, 1983), Sislet & Wood, Encyclopedia of Surface Active Agents (Chemical Publishing Co., Inc. 1964), McCutcheon's Emulsifiers & Detergents, North American and International Edition (McCutcheon Division, The MC Publishing Co., 1991), Ash, The Condensed Encyclopedia of Surfactants (Chemical Publishing Co., Inc., 1989), Ash, What Every Chemical Technologist Wants to Know About . . . Emulsifiers and Wetting Agents, Vol.
  • Such surfactants include Tetronic® 1307, Tetronic® 904, Tetronic® 1304, Tetronic® 1107 (BASF Corporation, Mount Olive, New Jersey) and Pluronic® F87 (BASF Corporation, Mount Olive, New Jersey).
  • the additional antimicrobial component may be any suitable, preferably ophthalmically acceptable, material effective to disinfect a contact lens contacted with the present solutions or alternatively adequately preserve a solution such as a contact lens rewetting solution.
  • the additional antimicrobial component is selected from biguanides, biguanide polymers, salts thereof and mixtures thereof, and is present in an amount in the range of about 0.1 ppm to about 3 ppm or less than 5 ppm (w/v).
  • the additional antimicrobial component may be a monomeric quaternary ammonium or biguanide compound such as chlorhexidine digluconate, chlorhexidine diacetate, benzethonium chloride and myristamidopropyldimethylamine.
  • the additional antimicrobial component may also be a polymeric quaternary ammonium compound such as Polyquad.RTM. (polyquatemium-1) or poly [oxyethylene (dimethyliminio) ethylene-(dimethyliminio) ethylene dichloride] (sold under the trademark WSCP by Buckman Laboratories, Inc.).
  • the preferred relatively reduced concentration of the additional antimicrobial component has been found to be very effective, in the present compositions, in disinfecting contact lenses contacted with the compositions, while at the same time promoting lens wearer/user comfort and acceptability.
  • any suitable, preferably ophthalmically acceptable viscosity inducing or thickening agent may be included in the present compositions.
  • the viscosity inducing component preferably is selected from cellulosic derivatives and mixtures thereof and is present in an amount in the range of about 0.05% or about 1.5% to about 3% or about 5.0% (w/v).
  • a viscosity inducing component at least assists in providing the lens wearer/user comfort and acceptability benefits of the present invention, which promote regular and consistent contact lens care and ultimately lead to or facilitate better ocular health.
  • the present combinations of components for example, including such viscosity inducing components, are effective in providing the degree of lens wearer/user comfort and acceptability benefits described herein.
  • an extremely useful tonicity component is a combination of sodium chloride and potassium chloride.
  • the present compositions preferably include an effective amount of a chelating component.
  • a chelating component Any suitable, preferably ophthalmically acceptable, chelating component may be included in the present compositions, although ethylenediaminetetraacetic acid (EDTA), salts thereof and mixtures thereof are particularly effective.
  • the present compositions include chelating components in effective amounts less than about 0.05% (w/v) and still more preferably 0.02°s (w/v) or less. Such reduced amounts of chelating component in the present compositions remain effective in providing the desired chelating and/or sequestering functions while, at the same time, are better tolerated in the eye, thereby reducing the risk of user discomfort and/or ocular irritation.
  • each of the components, in the concentration employed, included in the solutions and the formulated solutions of the present invention generally are ophthalmically acceptable.
  • each of the components (in the case of the CPC, in combination with the non-ionic surfactant as described above), in the concentration employed included in the present solutions usually is soluble in the liquid aqueous medium.
  • the solution may also optionally include an additional antimicrobial component in an amount effective to, in association with the remainder of the solution, disinfect a contact lens contacted with the composition.
  • a solution or component thereof is "ophthalmically acceptable" when it is compatible with ocular tissue, that is, it does not cause significant or undue detrimental effects when brought into contact with ocular tissue.
  • each component of the present compositions is also compatible with the other components of the present compositions.
  • the present compositions are more preferably substantially ophthalmically optimized.
  • An ophthalmically optimized composition is one which, within the constraints of component chemistry, minimizes ocular response, or conversely delivers ophthalmic benefit to the lens wearing eye.
  • the presently useful additional antimicrobial components include chemicals which derive their antimicrobial activity through a chemical or physiochemical interaction with microbes or microorganisms, such as those contaminating a contact lens.
  • Suitable additional antimicrobial components are those generally employed in ophthalmic applications and include, but are not limited to, quaternary ammonium salts used in ophthalmic applications such as poly [dimethylimino-2-butene-l, 4-diyl] chloride, alpha - [4-tris (2-hydroxyethyl) ammonium] -dichloride (chemical registry number 75345-27-6, available under, the trademark Polyquateraium 1® from Onyx Corporation), benzalkonium halides, and biguanides, such as salts of alexidine, alexidine-free base, salts of chlorhexidine, hexamethylene biguanides and their polymers, and salts thereof, antimicrobial polypeptides, chlorine dioxide precursors, and the like and mixtures thereof
  • PHMB hexamethylene biguanide polymers
  • PAPB polyaminopropyl biguanide
  • the antimicrobial component is present in the liquid aqueous medium at an ophthalmically acceptable or safe concentration such that the user can remove the disinfected lens from the liquid aqueous medium and thereafter directly place the lens in the eye for safe and comfortable wear.
  • the antimicrobial component is present in the liquid aqueous medium at an ophthalmically acceptable or safe concentration and sufficient for maintaining preservative effectiveness.
  • the additional antimicrobial components suitable for inclusion in the present invention include chlorine dioxide precursors.
  • chlorine dioxide precursors include stabilized chlorine dioxide (SCD), metal chlorites, such as alkali metal and alkaline earth metal chlorites, and the like and mixtures thereof.
  • Technical grade sodium chlorite is a very useful chlorine dioxide precursor.
  • Chlorine dioxide containing complexes such as complexes of chlorine dioxide with carbonate, chlorine dioxide with bicarbonate and- mixtures thereof are also included as chlorine dioxide precursors.
  • the exact chemical composition of many chlorine dioxide precursors, for example, SCD and the chlorine dioxide complexes, is not completely understood.
  • the manufacture or production of certain chlorine dioxide precursors is described in McNicholas, U.S. Patent 3,278,447, which is incorporated in its entirety herein by reference.
  • Specific examples of useful SCD products include that sold under the tiademark Dura Klor® by Rio Linda Chemical Company, Inc., and that sold under the trademark Anthium Dioxide® by International Dioxide, Inc.
  • a chlorine dioxide precursor in included in the present compositions it generally is present in an effective preservative or contact lens disinfecting amount.
  • Such effective preservative or disinfecting concentrations usually are in the range of about 0.002 to about 0.06% (w/v) of the present compositions.
  • the chlorine dioxide precursors may be used in combination with other antimicrobial components, such as biguanides, biguanide polymers, salts thereof and mixtures thereof.
  • the compositions usually have an osmolality of at least about 200 mOsmol/kg and are buffered to maintain the pH within an acceptable physiological range, for example, a range of about 6 to about 10.
  • compositions usually further comprise effective amounts of one or more additional components, such as a detergent or surfactant component; a viscosity inducing or thickening component; a chelating or sequestering component; a tonicity component; and the like and mixtures thereof.
  • additional component or components may be selected from • materials which are known to be useful in contact lens care compositions and are included in amounts effective to provide the desired effect or benefit.
  • an additional component is included, it is generally compatible under typical use and storage conditions with the other components of the composition.
  • the aforesaid additional component or components are substantially stable in the presence of the antimicrobial and buffer components described herein.
  • the viscosity inducing components employed in the present solutions preferably are effective at low or reduced concentrations, compatible with the other components of the present solutions, and anionic and non-ionic. Such viscosity inducing components are effective to enhance and/or prolong the cleaning and wetting activity of the surfactant component and/or condition the lens surface rendering it more hydrophilic (less lipophilic) and/or to act as a demulcent on the eye. Increasing the solution viscosity provides a film on the lens which may facilitate comfortable wearing of the treated contact lens. The viscosity inducing component may also act to cushion the impact on the eye surface during insertion and serves also to alleviate eye irritation.
  • Suitable viscosity inducing components include, but are not limited to, water soluble natural gums, cellulose-derived polymers and the like.
  • Useful natural gums include guar gum, gum tragacanth and the like.
  • Useful cellulose-derived viscosity inducing components include cellulose-derived polymers, such as hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose and the like. More preferably, the viscosity inducing agent is selected from cellulose derivatives (polymers) and mixtures thereof.
  • a very useful viscosity inducing component is hydroxypropylmethyl cellulose (HPMC).
  • a reduced amount is employed, for example, in the range of less than about 0.05% (w/v) or even about 0.02% (w/v) or less.
  • Such reduced amounts of chelating component have been found to be effective in the present compositions while, at the same time, providing for reduced cytotoxicity, discomfort and/or ocular irritation.
  • the liquid aqueous medium preferably includes an effective amount of a tonicity component to provide the liquid medium with the desired tonicity.
  • a tonicity component may be present in the liquid aqueous medium and/or may be introduced into the liquid aqueous medium.
  • suitable tonicity adjusting components that may be employed are those conventionally used in contact lens care products, such as various inorganic salts.
  • Sodium chloride and/or potassium chloride and the like are very useful tonicity components.
  • the amount of tonicity component included is effective to provide the desired degree of tonicity to the solution. Such amount may, for example, be in the range of about 0.1% to about 1.5% (w/v). If a combination of sodium chloride and potassium chloride is employed, it is preferred that the weight ratio of sodium chloride to potassium chloride be in the range of about 2.5 to about 6 or about 8.
  • Candida albicans ATCC 10231, is one of five organisms specified per FDA and ISO/CLI tests for the testing of contact lens disinfectants (FDA Premarket Notification (510k) Guidance Document for Contact Lens Care Products, Appendix A and B, May 1, 1997 and ISO/FDIS 14729: Ophthalmic optics-Contact lens care products- Microbiological requirements and test methods for products and regimens for hygienic management of contact lenses, January 2001).
  • Contact lens disinfectants are also known as contact lens multipurpose solutions when they are used for rinsing, cleaning, disinfection, storage and rewetting contact lenses.
  • the five FDA/ISO specified test organisms are listed below:
  • Candida albicans is often the most resistant of the five organisms to commonly used cationic antimicrobial agents in contact lens multi-purpose solutions. Thus, achievement of adequate antimicrobial activity against Candida is often the most difficult task to pass a particular disinfection efficacy standard.
  • FDA and ISO guidelines specify two disinfection efficacy standards, indicated in the table below: Stand Alone Disinfectant (Primary) Criteria: Organism Average log reduction at labeled soak time S. marcescens 3.0 logs S. aureus 3.0 logs P. aeruginosa 3.0 logs C. albicans 1.0 log F. solani 1.0 log

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Eyeglasses (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
PCT/US2005/011009 2004-04-07 2005-03-31 Cetylpyridinium chloride as an antimicrobial agent in ophthalmic compositions Ceased WO2005097960A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2007507379A JP2007532953A (ja) 2004-04-07 2005-03-31 眼科用組成物における抗微生物剤としての塩化セチルピリジニウム
BRPI0509654-5A BRPI0509654A (pt) 2004-04-07 2005-03-31 cloreto de cetilpiridìnio como agente antimicrobiano em composições oftálmicas
CA2562546A CA2562546C (en) 2004-04-07 2005-03-31 Cetylpyridinium chloride as an antimicrobial agent in ophthalmic compositions
EP05763160A EP1733014B1 (en) 2004-04-07 2005-03-31 Cetylpyridinium chloride as an antimicrobial agent in ophthalmic compositions
DE602005013498T DE602005013498D1 (de) 2004-04-07 2005-03-31 Cetylpyridiniumchlorid als antimikrobielles mittel in ophthalmischen zusammensetzungen
CN200580011933XA CN1942571B (zh) 2004-04-07 2005-03-31 氯化十六烷基吡啶鎓在眼药组合物中作为抗菌剂
AU2005230851A AU2005230851B2 (en) 2004-04-07 2005-03-31 Cetylpyridinium chloride as an antimicrobial agent in ophthalmic compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/820,486 2004-04-07
US10/820,486 US7578996B2 (en) 2004-04-07 2004-04-07 Cetylpyridinium chloride as an antimicrobial agent in ophthalmic compositions

Publications (1)

Publication Number Publication Date
WO2005097960A1 true WO2005097960A1 (en) 2005-10-20

Family

ID=34972927

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/011009 Ceased WO2005097960A1 (en) 2004-04-07 2005-03-31 Cetylpyridinium chloride as an antimicrobial agent in ophthalmic compositions

Country Status (11)

Country Link
US (2) US7578996B2 (enExample)
EP (1) EP1733014B1 (enExample)
JP (1) JP2007532953A (enExample)
CN (1) CN1942571B (enExample)
AT (1) ATE426655T1 (enExample)
AU (1) AU2005230851B2 (enExample)
BR (1) BRPI0509654A (enExample)
CA (1) CA2562546C (enExample)
DE (1) DE602005013498D1 (enExample)
ES (2) ES2321214T3 (enExample)
WO (1) WO2005097960A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075556A3 (en) * 2005-12-20 2007-09-07 Johnson & Johnson Vision Care Method for removing unreacted components from hydrogel ophthalmic lenses
WO2012080918A3 (en) * 2010-12-14 2012-11-22 Ecolab Usa Inc. Wear resistant antimicrobial compositions and methods of use
WO2018109456A1 (en) * 2016-12-12 2018-06-21 Provita Eurotech Ltd Antimicrobial compositions

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070264226A1 (en) * 2006-05-10 2007-11-15 Karagoezian Hampar L Synergistically enhanced disinfecting solutions
US8759321B2 (en) * 2007-06-13 2014-06-24 Bausch & Lomb Incorporated Ophthalmic composition with hyaluronic acid and polymeric biguanide
TWI551305B (zh) * 2007-08-31 2016-10-01 諾華公司 相對黏稠封裝溶液之用途
US9096819B2 (en) 2008-01-31 2015-08-04 Bausch & Lomb Incorporated Ophthalmic compositions with an amphoteric surfactant and an anionic biopolymer
US20110046033A1 (en) * 2008-01-31 2011-02-24 Jinzhong Zhang Multipurpose Lens Care Solution with Benefits to Corneal Epithelial Barrier Function
US8119112B2 (en) * 2008-01-31 2012-02-21 Bausch & Lomb Incorporated Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid
US20100286010A1 (en) * 2008-09-03 2010-11-11 Erning Xia Ophthalmic Compositions with Hyaluronic Acid
US9125405B2 (en) * 2008-10-28 2015-09-08 Bausch & Lomb Incorporated Contact lens solution with a tertiary amine oxide
US9872843B2 (en) * 2011-10-08 2018-01-23 Next Science, Llc Antimicrobial compositions and methods employing same
WO2013067544A1 (en) * 2011-11-06 2013-05-10 Nbip, Llc Anti-microbial compositions and related methods
CN102552914A (zh) * 2012-01-31 2012-07-11 江西科伦药业有限公司 一种能同时调节pH值及渗透压的组合物及其制备方法
US8324171B1 (en) 2012-02-06 2012-12-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US8664180B2 (en) 2012-02-06 2014-03-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
CN102835398A (zh) * 2012-09-28 2012-12-26 山东潍坊润丰化工有限公司 一种二氯吡啶酸胆碱水剂和原药的制备方法
MX380775B (es) * 2014-03-24 2025-03-12 Johnson & Son Inc S C Composiciones que contienen uno o varios ingredientes corrosivos que tienen toxicidad reducida y método de obtención.
EP3784354A1 (en) * 2018-04-27 2021-03-03 Allergan, Inc. Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity
JP7253128B2 (ja) * 2018-06-13 2023-04-06 京都バイオファーマ製薬株式会社 デプシペプチド系抗生物質を含有する外用組成物
US11253625B2 (en) * 2018-06-27 2022-02-22 Bausch & Lomb Incorporated Ophthalmic device packaging solutions comprising a poloxamine/erythritol mixture
GB201813229D0 (en) 2018-08-14 2018-09-26 Ocutec Ltd Formulation
AU2019343188A1 (en) * 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
WO2021110975A1 (en) * 2019-12-05 2021-06-10 Cis Pharma Ag High hyaluronate multi-purpose disinfection solutions for ophthalmic applications

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4043911A (en) * 1975-03-24 1977-08-23 Baylor College Of Medicine Sterilization of holding tanks and toilet bowls by quaternary compounds
WO1992016244A1 (en) * 1991-03-18 1992-10-01 Allergan, Inc. Contact lens disinfecting compositions
US5252246A (en) * 1992-01-10 1993-10-12 Allergan, Inc. Nonirritating nonionic surfactant compositions
WO1994027436A1 (en) * 1993-05-20 1994-12-08 Decicco Benedict T Preservative systems with enhanced antimicrobial activity
EP1149531A1 (en) * 2000-04-25 2001-10-31 Wako Pure Chemical Industries, Ltd. Anti-protista preparation
KR20020041118A (ko) * 2000-11-27 2002-06-01 김용철 박홍양 가금류의 뉴캐슬병의 치료 및 예방 제제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
USB724600I5 (enExample) * 1968-04-26
AR207548A1 (es) * 1972-08-11 1976-10-15 Flow Pharma Inc Composicion acuosa para limpiar y tratar lentes de contacto
US4758595A (en) 1984-12-11 1988-07-19 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US4908147A (en) 1986-02-19 1990-03-13 Ciba-Geigy Corporation Aqueous self preserving soft contact lens solution and method
US5110493A (en) 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
JP3297969B2 (ja) 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
EP0855187A3 (en) 1997-01-24 2001-01-17 Senju Pharmaceutical Co., Ltd. Agent for contact lenses
US20030228393A1 (en) * 2002-05-31 2003-12-11 Zhao Iris Ginron Multi-phase food & beverage
US6020375A (en) 1997-06-13 2000-02-01 Senju Pharmaceutical Co., Ltd. Bactericidal composition
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
JP3677421B2 (ja) * 1999-12-27 2005-08-03 扶桑薬品工業株式会社 涙液分泌促進組成物
TW200300448A (en) * 2001-11-21 2003-06-01 Novartis Ag Conditioning solution for contact lenses
WO2003047559A1 (en) * 2001-12-05 2003-06-12 Mitokor, Inc. Use of polycyclic phenolic compounds for the treatment of opthalmic diseases
US20040120916A1 (en) * 2002-12-23 2004-06-24 Advanced Medical Optics, Inc. Contact lens care compositions, methods of use and preparation which protect ocular tissue membrane integrity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4043911A (en) * 1975-03-24 1977-08-23 Baylor College Of Medicine Sterilization of holding tanks and toilet bowls by quaternary compounds
WO1992016244A1 (en) * 1991-03-18 1992-10-01 Allergan, Inc. Contact lens disinfecting compositions
US5252246A (en) * 1992-01-10 1993-10-12 Allergan, Inc. Nonirritating nonionic surfactant compositions
WO1994027436A1 (en) * 1993-05-20 1994-12-08 Decicco Benedict T Preservative systems with enhanced antimicrobial activity
EP1149531A1 (en) * 2000-04-25 2001-10-31 Wako Pure Chemical Industries, Ltd. Anti-protista preparation
KR20020041118A (ko) * 2000-11-27 2002-06-01 김용철 박홍양 가금류의 뉴캐슬병의 치료 및 예방 제제

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200301, Derwent World Patents Index; Class B03, AN 2003-010728, XP002344287 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075556A3 (en) * 2005-12-20 2007-09-07 Johnson & Johnson Vision Care Method for removing unreacted components from hydrogel ophthalmic lenses
US7776238B2 (en) 2005-12-20 2010-08-17 Vanderlaan Douglas G Methods and systems for leaching silicone hydrogel ophthalmic lenses
WO2012080918A3 (en) * 2010-12-14 2012-11-22 Ecolab Usa Inc. Wear resistant antimicrobial compositions and methods of use
US10912299B2 (en) 2010-12-14 2021-02-09 Ecolab Usa Inc. Wear resistant antimicrobial compositions and methods of use
US12414567B2 (en) 2010-12-14 2025-09-16 Ecolab Usa Inc. Wear resistant antimicrobial compositions and methods of use
WO2018109456A1 (en) * 2016-12-12 2018-06-21 Provita Eurotech Ltd Antimicrobial compositions

Also Published As

Publication number Publication date
CA2562546C (en) 2013-11-19
US7578996B2 (en) 2009-08-25
ES2323827A1 (es) 2009-07-24
ATE426655T1 (de) 2009-04-15
CA2562546A1 (en) 2005-10-20
EP1733014B1 (en) 2009-03-25
EP1733014A1 (en) 2006-12-20
ES2323827B1 (es) 2010-04-19
CN1942571B (zh) 2012-02-15
BRPI0509654A (pt) 2007-10-09
AU2005230851B2 (en) 2010-12-23
US20050226841A1 (en) 2005-10-13
AU2005230851A1 (en) 2005-10-20
US20090318512A1 (en) 2009-12-24
CN1942571A (zh) 2007-04-04
ES2321214T3 (es) 2009-06-03
JP2007532953A (ja) 2007-11-15
DE602005013498D1 (de) 2009-05-07

Similar Documents

Publication Publication Date Title
US20090318512A1 (en) Methods of maintaining ocular tissue cell membrane integrity using cetylpyridinium chloride
AU653768B2 (en) Method and composition for disinfecting contact lenses
AU745778B2 (en) Multi-purpose contact lens care compositions
EP1140224B1 (en) Contact lens cleaner comprising biguanide, tyloxapol and poloxamine
US6309596B1 (en) Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by a poloxamine
US20070059332A1 (en) Multi purpose contact lens care compositions including propylene glycol or glycerin
CA2562267C (en) Alkylamine as an antimicrobial agent in ophthalmic compositions
WO2006110482A2 (en) Borate-polyol mixtures as a buffering system
EP2430139A1 (en) Ophthalmic compositions with biguanide and peg-glycerol esters

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005763160

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 200650070

Country of ref document: ES

Kind code of ref document: A

Ref document number: 200650069

Country of ref document: ES

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P200650070

Country of ref document: ES

Ref document number: P200650069

Country of ref document: ES

Ref document number: 2562546

Country of ref document: CA

Ref document number: 2005230851

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580011933.X

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007507379

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005230851

Country of ref document: AU

Date of ref document: 20050331

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005230851

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005763160

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0509654

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 200650069

Country of ref document: ES

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 200650070

Country of ref document: ES

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 200650069

Country of ref document: ES

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 200650070

Country of ref document: ES

Kind code of ref document: A